



ASX / Media Release

9 June 2010

RHT: First International Distributor for FerriScan®

Resonance Health Ltd (ASX: RHT) is pleased to announce the appointment of its first international distributor for its FerriScan[®] service. OneS MediKal TIC. LTD will be representing Resonance Health in Turkey, firstly in gaining registration and reimbursement for FerriScan[®] and then in establishing the service in hospitals across the country.

OneS MediKal has a strong reputation for achieving significant sales success and is the distributor for several medical devices and diagnostics focused on the haematology market.

A decision on registration in Turkey is expected in the next few months. A substantial case has been developed for FerriScan[®] in Turkey by clinicians from approximately 20 medical institutions. A number of these doctors have been involved in clinical trials which have included the use of FerriScan[®] and who are now anxious to use the service for day-to-day management of their patients.

FerriScan[®], launched in 2005, is Resonance Health's core product and is currently available in over 20 countries. More than 8,000 FerriScans have been completed to date and the accurate measurement of liver iron with FerriScan[®] is recommended in patient management guidelines. Patients with elevated liver iron concentrations are at a greater risk of future cardiac complications and premature death.

Turkey has a high prevalence of thalassaemia major and sickle cell disease, often requiring regular blood transfusions in their treatment. In the course of these transfusions, patients may become iron loaded, primarily in the liver. There is also a high incidence of haemochromatosis, a hereditary disease whereby excess iron is absorbed from the diet and may accumulate in the liver and other organs. Accurate measurement of liver iron concentration is vital in informing clinician decisions on treatment options.

Resonance Health is currently expanding the availability of FerriScan[®] across Europe, where the service has regulatory approval under the CE mark and looks forward to its establishment in Turkey.

For further information please contact: **Resonance Health** Liza Dunne Managing Director T: + 61 8 9286 5300 E: lizad@resonancehealth.com

Eva O'Malley Company Secretary T + 61 8 9286 5300 E: evao@ferriscan.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing radiological image analysis services for the clinical and research communities. Its patented technology FerriScan® provides a safe and accurate alternative for measuring liver iron concentration, a significant issue for patients with iron overload. The Company continues to invest in research and development into other quantitative radiological imaging technologies.

Resonance Health Limited ABN: 96 006 762 492

1st Floor, 216 Stirling Hwy, Claremont, WA 6010, AUSTRALIA Postal: PO Box 1135, Nedlands, WA 6909, AUSTRALIA T: +61 (0) 8 9286 5300 F: +61 (0) 8 9286 5399 www.resonancehealth.com